Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215410 · ClinicalTrials.gov registry record · Phase 2
Study in Patients With Asthma
A Phase 2 study of Asthma, sponsored by Dey.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 12
- Study locations
NCT00215410: Completed Phase 2 study of Asthma, sponsored by Dey.
NCT00215410 is a Phase 2 study of Asthma that has completed, run by Dey. The registered enrollment target is 36 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 12 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00215410, a Phase 2 study of Asthma, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine the most safe and effective dose of the investigational drug in comparison with a control drug and placebo.
Conditions Studied
Interventions
- DRUG Formoterol Fumarate
Study Locations (12)
California
- Research Site - Long Beach
- Research Site - Mission Viejo
- Research Site - Newport Beach
- Research Site - Orange
- Research Site - Vista
Oregon
- Research Site - Medford
- Research Site - Portland
Texas
- Research Site - Fort Worth
- Research Site - Houston
Arkansas
- Research Site - Little Rock
Colorado
- Research Site - Englewood
Oklahoma
- Research Site - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
What the finished NCT00215410 record still lists
NCT00215410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Formoterol Fumarate is the first listed.
NCT00215410 lists 12 locations in 6 states (California, Oregon, Texas).
Frequently Asked Questions
What is clinical trial NCT00215410 about?
NCT00215410 is a clinical study titled "Study in Patients With Asthma". The purpose of this study is to determine the most safe and effective dose of the investigational drug in comparison with a control drug and placebo.
What is the current status of trial NCT00215410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. Estimated completion is 2005-10.
What conditions does trial NCT00215410 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00215410?
The interventions under investigation include: Formoterol Fumarate (DRUG).
Who is sponsoring clinical trial NCT00215410?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00215410 being conducted?
This trial has 12 study locations across Arkansas, California, Colorado, Oklahoma, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00215410's enrollment target sits among peer trials
36 287th of 374 higher than 83 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer